A detailed history of Jane Street Group, LLC transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 18,847 shares of ITOS stock, worth $136,829. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,847
Previous 159,855 88.21%
Holding current value
$136,829
Previous $2.37 Million 91.91%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.09 - $17.97 $1.42 Million - $2.53 Million
-141,008 Reduced 88.21%
18,847 $192,000
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $1.65 Million - $2.89 Million
159,855 New
159,855 $2.37 Million
Q4 2023

Feb 14, 2024

BUY
$8.57 - $11.06 $111,324 - $143,669
12,990 Added 118.71%
23,933 $262,000
Q3 2023

Nov 14, 2023

SELL
$10.95 - $14.6 $549,602 - $732,803
-50,192 Reduced 82.1%
10,943 $119,000
Q2 2023

Aug 14, 2023

BUY
$12.93 - $18.05 $790,475 - $1.1 Million
61,135 New
61,135 $809,000
Q4 2022

Feb 14, 2023

SELL
$17.77 - $21.6 $27,614 - $33,566
-1,554 Reduced 10.17%
13,733 $268,000
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $53,642 - $78,589
2,884 Added 23.25%
15,287 $291,000
Q2 2022

Aug 16, 2022

BUY
$16.57 - $35.1 $58,309 - $123,516
3,519 Added 39.61%
12,403 $256,000
Q1 2022

May 17, 2022

SELL
$31.92 - $47.45 $190,530 - $283,229
-5,969 Reduced 40.19%
8,884 $286,000
Q4 2021

Feb 15, 2022

BUY
$26.23 - $47.86 $389,594 - $710,864
14,853 New
14,853 $692,000
Q2 2021

Aug 16, 2021

SELL
$17.9 - $36.1 $199,549 - $402,442
-11,148 Closed
0 $0
Q1 2021

May 18, 2021

BUY
$30.86 - $44.2 $344,027 - $492,741
11,148 New
11,148 $381,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $258M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.